MAM
Adfest 2016: Dentsu’s Yoshiro Yagi is Design & Print Craft Lotus jury president
MUMBAI: Dentsu Inc CD Yoshiro Yagi has been appointed Design Lotus & Print Craft Lotus jury president at Adfest 2016.
“I’m really glad that I can come back to Adfest as the Jury President for Design and Print Craft. I love the different aesthetics that originate in Asia, and I’m very excited about discovering new works created by some of the best designers and art directors in the world,” says Yagi.
Yagi is one of the most internationally awarded art directors in Japan, and perhaps in Asia. After leaving high school temporarily to hone his talents as a rhythmic gymnast, he later discovered his passion for creativity and enrolled at Kyoto University of Art and Design. After graduating, he joined Dentsu in 2001 to start his career as an art director. Since then, he has won over 150 awards including two Grand Prix at Adfest, Best of Design at One Show, and 28 Lions at Cannes.
He has worked for major clients such as East Japan Railway, Panasonic, Honda and Menicon.
“Yoshihiro has an eye for simplicity, but he is also fascinated with mixing and editing different media forms, which is what makes him unique as an art-trained Creative Director. Not only does he understand the principles of good design, but he also knows when to break the rules, which is why he’ll make such an excellent Jury President of Design and Print Craft at Adfest 2016,” adds Adfest president Jimmy Lam.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
